On October 7, JOINN fell 9.57% in regular trading, trading at HK$29.34/share, with Turnover of HK$2.272 million.
The decline came as CRO concept stocks broadly weakened, with GENSCRIPT BIO dropping 14.73%, INSILICO down 6.75%, XTALPI down 6.02%, WUXI BIO down 2.59%, and WUXI APPTEC down 1.10%, driving sector-wide linkage effects. Recent institutional activity had been mixed: Morgan Stanley increased its H-share long position to 5.23% on September 29, while GF Fund Management reduced its stake from 5.14% to 4.82% on September 28, contributing to heightened short-term volatility.
JOINN operates through three segments including non-clinical drug research services, clinical services, and experimental model supply, providing services in both domestic and overseas markets.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)